ArticleCancer medicine2023

Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study.

Jingyi Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.